Loading news...
Valneva (NASDAQ: VALN - Get Free Report) and Sharps Technology (NASDAQ: STSS - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Insider and Institutional Ownership 11.4% of Valneva shares
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”) (NASDAQ: STSS), a medical device company with a Solana (SOL) digital asset treasury strategy, and BitGo Bank & Trust, National Association (“BitGo”), the digital asset infrastructure company, today announced a strategic collaboration under which STSS will expand and further institutionalize its Solana treasury strategy through BitGo's services. As part of this arrangement, STSS intends to utilize BitGo's institutional-grade qualified custody through its OCC regulated entity, BitGo Bank & Trust, National Association.
Sharps Technology, Inc. (NASDAQ: STSS - Get Free Report) major shareholder Saba Capital Management, L.P. sold 77,688 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $2.25, for a total transaction of $174,798.00. Following the completion of the sale, the insider directly owned 1,549,170
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) today announced that it has entered into a 90-day lock-up agreement with SOL Markets (the “Strategic Advisor”), pursuant to which SOL Markets has agreed to restrict sales of its advisory warrants and any underlying shares. The lock-up reflects strong conviction in STSS's execution roadmap and reinforces alignment between the parties. This comes after the company's recent announcement that its Board of Directors approved a share buyback program for up to $100 million.
MacroGenics (NASDAQ: MGNX - Get Free Report) and Sharps Technology (NASDAQ: STSS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Earnings and Valuation This table compares MacroGenics and
NEW YORK , Oct. 9, 2025 /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ: STSS) and Coinbase Global, Inc ("Coinbase"), one of the world's largest digital asset services platforms, today announced a strategic collaboration whereby STSS will expand its previously announced Solana digital asset treasury strategy with Coinbase. STSS has acquired over 2 million SOL to-date, which are currently valued at over $400 million with SOL trading at over $210.
NEW YORK , Oct. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ: STSS) today announced a stock repurchase program to acquire up to $100 million of the company's outstanding common stock. This new stock repurchase program will enable the company to repurchase its shares in the open market and in negotiated transactions.
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- Crypto.com and Sharps Technology, Inc. (the "Company" or "STSS") (Nasdaq: "STSS" and "STSSW") today announced that STSS has expanded its digital asset treasury strategy with Crypto.com services for its holdings.
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ: STSS), a medical device company with a Solana digital asset treasury strategy, and Jupiter Exchange ("Jupiter"), one of Solana's leading decentralized finance (DeFi) superapps, today announced a strategic partnership to utilize Jupiter's staking infrastructure as part of STSS's treasury strategy.
/PRNewswire/ -- Sharps Technology ("Sharps Technology" or the "Company") (NASDAQ: STSS), a medical device company with a Solana digital asset treasury, and
NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Sharps Technology ("Sharps Technology" or the "Company") (NASDAQ: STSS), a leading publicly listed Solana treasury, and Pudgy Penguins, the globally recognized Web3 brand, today announced a strategic partnership to bring exposure and connectivity to the Solana digital asset treasury space.
Sharps Technology stock (NASDAQ: STSS) surged 56% on Wednesday, following the company's announcement of a $400 million private placement to create the largest Solana blockchain-backed digital asset treasury in the corporate sector.
Investors include leading financial institutions and digital asset market leaders such as ParaFi, Pantera, Monarq, FalconX, Phoenix Capital, Bastion Trading, RockawayX, Syncracy, Borderless, Republic Digital, Arche Capital, CoinFund, Arrington Capital, Quantstamp, CoinList Alpha, Primitive Ventures, Avenir, Hypersphere, and more NEW YORK , Aug. 25, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced the pricing of a private placement offering to support its plans to adopt a digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Solana is the fastest and most used public blockchain in the world, processing more transactions and generating more onchain fee revenue than all other blockchains combined.
Shares of Sharps Technology jumped after the company said it has initiated a second shipment from its first commercial order of SoloGard syringes.
Second commercial delivery underway as part of multi-year contract with leading U.S. healthcare partner Strategic manufacturing upgrades drive scalability, efficiency, and increases capacity to support production growth NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced an update on the execution of its first shipments under the previously announced $50 million SoloGard sales agreement, alongside a series of advanced manufacturing upgrades. Sharps has initiated the second shipment of its first commercial order of SoloGard syringes under a multi-year supply agreement with a U.S.-based leader in IV flushing solutions.
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on June 12th, 2025 at 9:30 AM ET. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements.
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com